（文章来源：证券日报） 证券日报网讯 11月10日晚间，圣诺生物发布公告称，2025年中期利润分配方案为每股现金红利0.03176 元（含税），股权登记日为2025年11月14日，除权（息）日为2025年11月17日。 ...

证券代码：688117 证券简称：圣诺生物 公告编号：2025-032 成都圣诺生物科技股份有限公司 2025年中期权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次利润分配方案经公司2025 年 5 月 15 日的2024年年度股东大会授权董事会 在满足现金分红的条件下具体制定，并经 2025 年 10 月 27 日召开的第四届董事会 第二十七次会议审议通过。 二、 分配方案 重要内容提示： 1. 发放年度：2025年中期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/11/14 | 2025/11/17 | 2025/11/17 | 2. 分派对象： 一、 通过分配方案的股东会届次和日期 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0.03176元 相关日期 3. 分配方案： 本次利润 ...

本次股权登记日：2025年11月14日；除权除息日为：2025年11月17日。 格隆汇11月10日丨圣诺生物(688117.SH)发布2025年半年度权益分派实施公告，分配方案的具体内容如 下：本次利润分配以方案实施前的公司总股本1.57亿股为基数，每股派发现金红利0.03176元（含税）， 共计派发现金红利499.86万元。 ...

本次股权登记日：2025年11月14日；除权除息日为：2025年11月17日。 格隆汇11月10日丨圣诺生物(688117.SH)发布2025年半年度权益分派实施公告，分配方案的具体内容如 下：本次利润分配以方案实施前的公司总股本1.57亿股为基数，每股派发现金红利0.03176元（含税）， 共计派发现金红利499.86万元。 ...

Group 1 - The core advantage of generic drugs is the lower R&D investment required [1] - GLP-1 peptide drugs are well-known for their triple benefits: blood sugar reduction, weight loss, and cardiovascular protection, making them a highly competitive area in innovative pharmaceuticals [3] - Saintno Biological (688117.SH), a company listed on the Sci-Tech Innovation Board, focuses on providing CDMO services for innovative peptide drugs and developing raw materials and formulations for generic peptides [4][5] Group 2 - According to the third-quarter earnings forecast disclosed by Saintno Biological in mid-October, the expected net profit for the first three quarters is between 114 million to 140 million, representing a year-on-year growth of 100.53% to 145.10% [6] - The expected non-net profit for the same period is between 113 million to 138 million, with a year-on-year growth of 111.26% to 158.21% [6]

Group 1 - The CRO index experienced fluctuations and a downward trend on November 4th [1] - Among the constituent stocks, Shengnuo Bio, Hongbo Pharmaceutical, and Chengdu XianDao had the largest declines, with decreases of 3.80%, 3.79%, and 3.53% respectively [1]

Core Viewpoint - The article highlights a significant surge in the innovative drug sector in China, driven by the introduction of a new commercial insurance innovation drug directory and an increase in business development (BD) activities for domestic innovative drugs, indicating a shift towards global market integration [3][6][8]. Group 1: Market Performance - On October 31, A-share innovative drug stocks experienced a collective surge, with notable gains such as 20% limit-up for Sangfor and 19.99% for Shuyitai [4][5]. - Other stocks like Zai Lab and Yifang Bio also saw increases exceeding 10%, reflecting a strong market sentiment towards innovative drugs [4][5]. Group 2: Policy Changes - The 2025 National Medical Insurance negotiations commenced on October 30, introducing a "commercial insurance innovation drug directory" mechanism, which aims to include innovative drugs that are not yet part of the basic medical insurance directory but have high clinical value [6][7]. - A total of 121 drug names passed the preliminary review for the commercial insurance directory, indicating a robust pipeline of innovative drugs awaiting approval [6]. Group 3: Business Development Activities - There has been a notable acceleration in the "going global" strategy for Chinese innovative drugs, with significant BD transactions reported, including a $11.4 billion deal between Innovent Biologics and Takeda [8][9]. - As of October 21, 2023, there were 115 licensing agreements for Chinese innovative drugs, totaling $101.24 billion, surpassing the entire amount for 2024 [8][9]. Group 4: Industry Outlook - Analysts suggest that the innovative drug sector in China is transitioning from a focus on generics to a more robust innovative landscape, with a long-term positive growth trend evident in BD transaction volumes [9]. - The introduction of the commercial insurance directory is expected to create broader market opportunities for innovative drugs, enhancing their commercial viability [6][7].

Core Viewpoint - The innovation drug sector in China is experiencing a significant surge, driven by the introduction of a new commercial insurance innovation drug directory and an acceleration in international business development (BD) activities for domestic innovative drugs [1][4][6]. Group 1: Market Performance - On October 31, A-share innovative drug concept stocks collectively surged, with companies like Sanofi and Shuyou Pharmaceutical hitting a 20% limit up, while others like Zai Lab and Yifang Bio saw increases exceeding 10% [2][3]. - The Hong Kong stock market also showed strength in the innovative drug sector, with companies such as InnoCare and Sanofi Pharmaceutical rising over 11% [2]. Group 2: Policy Changes - The 2025 National Medical Insurance Negotiation commenced on October 30, introducing a "commercial insurance innovation drug directory" mechanism for the first time, which aims to include innovative drugs that are not yet part of the basic medical insurance directory but have high clinical value [4]. - A total of 535 drug names passed the formal review for the basic drug directory, while 121 drug names were approved for the commercial insurance innovation drug directory, indicating a significant focus on high-innovation drugs [4]. Group 3: Business Development Acceleration - Since October, there has been a notable increase in the "outbound" progress of domestic innovative drugs, with several high-profile BD transactions, including a strategic cooperation deal worth up to $11.4 billion between Innovent Biologics and Takeda [6][7]. - As of October 21, 2023, there were 115 outbound licensing agreements for Chinese innovative drugs, totaling $101.24 billion, significantly surpassing the $51.9 billion for the entire year of 2024 [7]. Group 4: Industry Outlook - Analysts indicate that the recent surge in BD transactions reflects China's innovative drug industry entering the global mainstream, transitioning from a focus on generic drugs to becoming a leader in certain areas of innovation [7][8]. - The Chinese pharmaceutical industry has completed a transformation from old to new growth drivers, with innovative drugs opening new growth avenues for companies [8].

Core Insights - The company, Shengnuo Biopharmaceuticals, reported significant growth in revenue and net profit for the first three quarters of 2025, primarily driven by increased overseas sales of GLP-1 class drugs, Semaglutide and Tirzepatide [1][2] - The company achieved a revenue of 520 million yuan, a year-on-year increase of 53.96%, and a net profit of 127 million yuan, reflecting a 123.03% increase [1] - The raw material drug business has become a major performance support for the company, with raw material revenue in the first half of the year reaching 189 million yuan, a 232.3% increase, accounting for approximately 55.92% of total revenue [1] Company Developments - Shengnuo Biopharmaceuticals is expanding its production capacity through various projects, including a new production line for peptide raw materials and technological upgrades for formulation industrialization [2] - The company’s raw materials are primarily sold overseas, and the expiration of patents for popular peptide drugs like Semaglutide in 2026 is expected to accelerate the penetration of generic drugs, leading to increased demand for peptide raw materials [2] Industry Context - The competition in the GLP-1 raw material drug market is intensifying, with several domestic companies such as Pro Pharmaceutical, Nuotai Biotech, and Hanyu Pharmaceutical also involved [2] - The market for oral peptide formulations is anticipated to drive higher demand for raw materials, presenting new growth opportunities for companies that strategically invest in this area [2] - The original manufacturer of Semaglutide, Novo Nordisk, has lowered its annual performance guidance, raising questions about the sustainability of the current market dynamics [2]

Core Insights - The company, Saint Noble Biotechnology (688117.SH), reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance [1] Financial Performance - Total operating revenue reached 520 million yuan, representing a year-on-year growth of 53.96% [1] - Net profit attributable to shareholders was 127 million yuan, showing a year-on-year increase of 123.03% [1] - Basic earnings per share were reported at 0.81 yuan [1] Dividend Announcement - The company plans to distribute a cash dividend of 0.3176 yuan (including tax) for every 10 shares to all shareholders [1]